A placebo-controlled, randomised, double-blind, single dose proof of concept study of DIMS-0150 [Kappaproct], in steroid resistant or steroid dependent patients with ulcerative colitis of mild to moderate degree.

Trial Profile

A placebo-controlled, randomised, double-blind, single dose proof of concept study of DIMS-0150 [Kappaproct], in steroid resistant or steroid dependent patients with ulcerative colitis of mild to moderate degree.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2014

At a glance

  • Drugs Cobitolimod (Primary)
  • Indications Ulcerative colitis
  • Focus Pharmacodynamics; Proof of concept; Therapeutic Use
  • Sponsors InDex Pharmaceuticals
  • Most Recent Events

    • 12 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top